Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

7.930 -0.300 (-3.65%)
Delayed Quote Updated: 4:00 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,693
Open 8.370
Bid (Size) 7.680 (300)
Ask (Size) 10.09 (400)
Prev. Close 8.230
Today's Range 7.695 - 8.410
52wk Range 3.920 - 19.14
Shares Outstanding 101,102,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
From Atara Biotherapeutics, Inc.
Via Business Wire

Performance

52-Week Range 58.6% below 52-week high
7.930
3.9252W Low 19.1452W High
1 Week 5.3% below 1-week high
7.471W Low 8.381W High

Atara Biotherapeutics, Inc. - Common Stock (ATRA) traded between $3.92 and $19.14 over the past 52 weeks and last traded at $7.93, 58.6% below its 52-week high. Over the past week it ranged between $7.47 and $8.38.

Past 12 Months
-0.4%
-15.5%
-14.0%
-24.3%
-55.4%
-36.9%
1W -$0.03
1M -$1.45
3M -$1.29
6M -$2.55
YTD -$9.84
1Y -$4.63

ATRA was -36.9% over the past year, -24.3% over six months, -55.4% year to date, -0.4% in the last week.

12 Months vs Market
ATRA
-36.9%
DIA
+9.0%
SPY
+10.9%
QQQ
+10.7%
IWM
+14.0%

Over the past 12 months ATRA returned -36.9% versus DIA (Dow) +9.0%, SPY (S&P 500) +10.9%, QQQ (Nasdaq 100) +10.7% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 0.42× 3-mo avg
Today 16,693 3-mo avg 39.6K
1W
20.6K
1M
23.1K
3M
39.6K
6M
71.2K
YTD
553.5K
1Y
486.3K

ATRA most recently traded 16,693 shares against a 3-month average daily volume of 39.6K.

More News

Read More
News headline image
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Changes to Its Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ATARA DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Which stocks have an unusual volume on Friday? ↗
Via Chartmill
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?
Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market
What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
The current price of Atara Biotherapeutics, Inc. - Common Stock is 7.930
When was Atara Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 11/12/26 04:00 PM ET
What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 801.74M
How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
Atara Biotherapeutics, Inc. - Common Stock has 802M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.